BACKGROUND AND OBJECTIVE:Vesicoureteral reflux (VUR) is diagnosed in ∼30% to 40% of children who have imaging studies after urinary tract infections (UTIs). Our goal is to characterize children enrolled in the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial and to compare our study cohort with those from previously published studies. METHODS: RIVUR investigators from 19 pediatric sites in the United States recruited 607 children with grade I through IV VUR. Children were enrolled after a first or second UTI. This cross-sectional report of baseline data includes extensive clinical, parental report, and imaging study results. RESULTS: RIVUR recruited 607 children (558 girls, 49 boys) with grade I (11%), II (42%), III (38%), or IV (8%) reflux. The median age was 12 months, and most children (91%) were enrolled after their first UTI. The UTI leading to enrollment was both febrile and symptomatic for 323 children, febrile only in 197 children, and symptomatic only in 86. Renal involvement at baseline as documented by a (99m)Tc dimercaptosuccinic acid scan was uncommon with cortical defects identified in 89 (15%) children. Bladder and bowel dysfunction was identified in 71 (56%) of 126 toilet-trained subjects assessed. CONCLUSIONS: RIVUR is the largest prospective, randomized trial for children with primary VUR to date, comparing prophylaxis with placebo. The study sample comprises patients from 19 pediatric clinical sites in the United States, whose demographic and clinical characteristics may differ from those of children enrolled in previous trials from other countries.
RCT Entities:
BACKGROUND AND OBJECTIVE: Vesicoureteral reflux (VUR) is diagnosed in ∼30% to 40% of children who have imaging studies after urinary tract infections (UTIs). Our goal is to characterize children enrolled in the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial and to compare our study cohort with those from previously published studies. METHODS: RIVUR investigators from 19 pediatric sites in the United States recruited 607 children with grade I through IV VUR. Children were enrolled after a first or second UTI. This cross-sectional report of baseline data includes extensive clinical, parental report, and imaging study results. RESULTS: RIVUR recruited 607 children (558 girls, 49 boys) with grade I (11%), II (42%), III (38%), or IV (8%) reflux. The median age was 12 months, and most children (91%) were enrolled after their first UTI. The UTI leading to enrollment was both febrile and symptomatic for 323 children, febrile only in 197 children, and symptomatic only in 86. Renal involvement at baseline as documented by a (99m)Tcdimercaptosuccinic acid scan was uncommon with cortical defects identified in 89 (15%) children. Bladder and bowel dysfunction was identified in 71 (56%) of 126 toilet-trained subjects assessed. CONCLUSIONS: RIVUR is the largest prospective, randomized trial for children with primary VUR to date, comparing prophylaxis with placebo. The study sample comprises patients from 19 pediatric clinical sites in the United States, whose demographic and clinical characteristics may differ from those of children enrolled in previous trials from other countries.
Authors: Julian Wan; Steven J Skoog; William C Hulbert; Anthony J Casale; Saul P Greenfield; Earl Y Cheng; Craig A Peters Journal: Pediatrics Date: 2012-03-12 Impact factor: 7.124
Authors: Alejandro Hoberman; Martin Charron; Robert W Hickey; Marc Baskin; Diana H Kearney; Ellen R Wald Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Tej K Mattoo; Steven J Skoog; Lisa Gravens-Mueller; Russell W Chesney; Alejandro Hoberman; Ranjiv Mathews; Marva Moxey-Mims; Anastasia Ivanova; Saul P Greenfield; Myra A Carpenter Journal: J Pediatr Urol Date: 2017-06-01 Impact factor: 1.830
Authors: Jessica C Lloyd; Talitha Yen; Ricardo Pietrobon; John S Wiener; Sherry S Ross; Paul J Kokorowski; Caleb P Nelson; Jonathan C Routh Journal: J Pediatr Urol Date: 2014-04-04 Impact factor: 1.830
Authors: Alejandro Hoberman; Saul P Greenfield; Tej K Mattoo; Ron Keren; Ranjiv Mathews; Hans G Pohl; Bradley P Kropp; Steven J Skoog; Caleb P Nelson; Marva Moxey-Mims; Russell W Chesney; Myra A Carpenter Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245
Authors: Caleb P Nelson; Alejandro Hoberman; Nader Shaikh; Ron Keren; Ranjiv Mathews; Saul P Greenfield; Tej K Mattoo; Nathan Gotman; Anastasia Ivanova; Marva Moxey-Mims; Myra A Carpenter; Russell W Chesney Journal: Pediatrics Date: 2016-03-11 Impact factor: 7.124
Authors: Anthony J Schaeffer; Saul P Greenfield; Anastasia Ivanova; Gang Cui; J Michael Zerin; Jeanne S Chow; Alejandro Hoberman; Ranjiv I Mathews; Tej K Mattoo; Myra A Carpenter; Marva Moxey-Mims; Russell W Chesney; Caleb P Nelson Journal: J Pediatr Urol Date: 2016-09-06 Impact factor: 1.830